Loading stock data…
Elevance Health, Inc. (ELV)
$401.94-5.56 (-1.36%)
Market ClosedLast close Sep 8
Elevance Health, Inc., together with its subsidiaries, operates as a health benefits company in the United States.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Elevance Health, Inc. in the Healthcare sector is trading at $401.94 with a market capitalization of $85.5B. Wall Street consensus targets $449.10 (21 analysts), implying a +11.7% move over the next 12 months. The stock is currently 8% below its 52-week high of $436.24, remaining 12.3% above its 200-day moving average. On fundamentals, Piotroski 4/9 shows mixed financial quality. The Whystock Score of 90/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +11.7% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $50.47B↑ | $50.18B↑ | $49.75B↓ | $50.71B↑ | $49.78B |
| Gross Profit | — | — | — | — | — |
| Operating Income | $2.30B↓ | $2.66B↑ | $581.00M↓ | $1.76B↓ | $2.63B |
| Net Income | $1.46B↓ | $1.76B↑ | $547.00M↓ | $1.19B↓ | $1.74B |
Peer Comparison
JNJUNHPFE
Fundamentals
Elevance Health, Inc., together with its subsidiaries, operates as a health benefits company in the United States. The company operates in four segments: Health Benefits, CarelonRx, Carelon Services, and Corporate & Other. It offers a variety of heal...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$85.49B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
17.42
Beta
Defensive asset. Lower volatility than the S&P 500.
0.69
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
1.71%
ROE
Average efficiency. Growth may require heavy reinvestment.
11.06%
Volume
Today's trading volume
1.16M
Recent News
Insurers Have Already Told Wall Street Which Advantage Plans Die on December 31. Members Are the Last to Know, and the Letter Isn’t Due Until October 2.
Insurers spent the summer telling Wall Street exactly which Medicare Advantage plans are disappearing on December 31. Enrolled members get a letter in October, a closing enrollment window in December, and a rare legal protection most will never realize they have.
Elevance Health (ELV) Stock Still Looks Undervalued Despite Its 37% Run
After a strong 37.5% return over the past year, Elevance Health now trades with a high value score and an undervalued read on market multiples, which raises the question of whether the recent share price strength has fully reflected that signal or not. Elevance Health has delivered a 37.5% 1 year return, so any further upside now depends on how much fundamental value is still not priced in. The appointment of Dr. Patrick Fox to lead Carelon Behavioral Services, alongside greater use of AI in...
UnitedHealth Stock Rises 39% in 6 Months: Should Investors Still Buy?
UNH's 39% six-month rally reflects improving medical costs, stronger earnings estimates and a sharper focus on profitable businesses.
UnitedHealth Stock Recovered Before Its Margins Did
UnitedHealth (UNH) stock has gained about 41% since early March, and at roughly $400 a share the market has already paid for a recovery. The easy reading is that the turnaround is finished. It is not. One half got better over those six months, the other got worse, and the price reflects the good half.
Is UnitedHealth Finally Turning the Corner After a Tough 2025?
UNH is showing signs of recovery as medical costs improve, Optum gains momentum and 2026 earnings guidance rises.